|Dr. Jay R. Luly Ph.D.||Chief Exec. Officer, Pres & Director||867.84k||N/A||61|
|Mr. Paul J. Mellett Jr.||Sr. VP-Fin. & Admin. and CFO||513.18k||N/A||62|
|Dr. Yat Sun Or Ph.D.||Sr. VP-R&D and Chief Scientific Officer||564.64k||N/A||65|
|Mr. Nathaniel S. Gardiner J.D.||Sr. VP, Gen. Counsel & Sec.||N/A||N/A||63|
|Dr. Timothy D. Ocain Ph.D.||Sr. VP of New Product Strategy & Devel.||N/A||N/A||59|
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The companys research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 6.